InvestorsHub Logo
Followers 15
Posts 515
Boards Moderated 0
Alias Born 04/21/2013

Re: None

Saturday, 11/06/2021 7:39:46 PM

Saturday, November 06, 2021 7:39:46 PM

Post# of 403217

This is a small stretch, but here is an excerpt from a report from a Russian doc. He was the head of research for many clinical trials, including Brilacidin. I believe the promising drug he is talking about is ours. Nikita Lomakin is his name . Look him up on , wait for it….. Facebook. The link to this report is on his page. I’ll try to post a link if I can figure it out.

Of course, we are fighting them, but not yet effectively enough. Pathogenetic therapy does not resonate in all patients. Our center has already conducted more than 20 clinical trials of Russian, American, German, Korean and other anticovid drugs. In the clinical trial phase, it is a promising American drug. Our task is to find the right medicine. But for now, it's a matter of the future. Therefore, today the main hopes have to be pinned on vaccines. And although new strains appear that really differ, they do not differ radically. Only a qualitative change in spike protein, with which the virus joins the host cell, will make existing vaccines ineffective
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News